Overview
Ashland fiscal Q3 revenue down 15%, missing analyst expectations, per LSEG data
Adjusted EPS for fiscal Q3 misses consensus, reflecting demand challenges and portfolio optimization
Net loss of $742 million primarily due to non-cash goodwill impairment charge
Outlook
Ashland expects FY2025 sales of $1.825 bln to $1.850 bln
Company projects FY2025 Adjusted EBITDA of $400 mln to $410 mln
Ashland sees stable macro environment with mixed demand trends
Tariff-related uncertainty persists, no material FY2025 impact expected
Result Drivers
PORTFOLIO OPTIMIZATION - Initiatives reduced sales by $53 mln, impacting revenue and adjusted EBITDA
SOFTER DEMAND - Personal Care and Specialty Additives faced subdued demand, contributing to revenue decline
PHARMA GROWTH - Life Sciences segment maintained growth momentum in pharma applications despite overall sales decline
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$463 mln
$476.40 mln (7 Analysts)
Q3 Adjusted EPS
Miss
$1.04
$1.23 (9 Analysts)
Q3 EPS
-$16.21
Q3 Net Income
-$742 mln
Q3 Adjusted EBITDA
Miss
$113 mln
$115.10 mln (10 Analysts)
Q3 Free Cash Flow
$108 mln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the diversified chemicals peer group is "buy"
Wall Street's median 12-month price target for Ashland Inc is $62.00, about 17.8% above its July 28 closing price of $50.95
The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 12 three months ago
Press Release: ID:nGNX7CxwPC
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)